No Data
No Data
Reported Earlier: 'Texas Lawmakers Take Up Bills To Expedite Access To Psychedelic Therapy' - Marijuana Moment
Express News | Compass Pathways PLC - Top-Line 6-Week Primary Endpoint Results Expected in Late June
Express News | Compass Pathways Announces Dosing Complete for All Participants in Part a of Phase 3 Comp005 Trial of Comp360 Psilocybin for Treatment-Resistant Depression
Stifel Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $11
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Argenx Se (ARGX) and COMPASS Pathways (CMPS)
Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $17